Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This will be an open label study of escitalopram. Patients not responsive to citalopram will
be switched directly to escitalopram.
Patients will receive escalating doses of escitalopram up to a maximum of 50 mg until they
either achieve remission (MADRS <9) or fail to tolerate the dose.